The Company in a Nutshell
| Date Reviewed | 11/28/2025 |
| Company Name | International Flavors & Fragrances Inc |
| Symbol | IFF |
| Sector | Materials |
| Industry | Specialty Chemicals |
| Beta | 1.07 |
| PRO Rating | 2 |
| Dividend Safety | 1 |
Business Model
International Flavors & Fragrances Inc. is a creator and manufacturer of food, beverage, health and biosciences, scent, and complementary adjacent products. The Company's segment includes Taste, Food Ingredients, Health & Biosciences, and Scent. The Taste segment consists of a range of flavor compounds and natural taste solutions used in food and beverage applications. The Food Ingredients segment includes a broad portfolio of natural and plant-based specialty ingredients that provide texturizing and food protection capabilities, as well as soy and pea protein solutions, emulsifiers, and sweeteners. Its Health & Biosciences segment consists of the development and production of an advanced biotechnology-derived portfolio of enzymes, food cultures, probiotics and specialty ingredients for food and non-food applications. Its Scent segment creates fragrance compounds and fragrance ingredients that are integral elements in perfumes and household and personal care products.
| Current price | 70.14 |
| ROE | 1.70 % |
| ROIC | 4.15 % |
| Shareholder Yield | 0.45 % |
| 5-Yr Total Return | -33.70 % |
| 1-Yr Total Return | -14.85 % |
| Next Earnings Date | 02-16-26 |
Latest Quarter Information
What the CEO said:
“Sales momentum in Scent and Taste remain solid, supported by strong new‑win contributions,” said CEO Erik Fyrwald. He noted that despite short-term challenges in other segments, “profitability improved” due to margin expansion driven by productivity. Fyrwald reaffirmed the company’s guidance and emphasized ongoing efforts to “unlock the full potential of our portfolio and create lasting value for shareholders” through disciplined execution and portfolio optimization.
What we say:
2025-11-27, International Flavors & Fragrances Inc reported a weak quarter performance on EPS and revenue with -30.4% and -7.9% respectively. IFF’s Q3 2025 revenue fell 8% to $2.69B, but was flat on a comparable basis as growth in Scent and Taste offset declines in Health & Biosciences and softness in protein solutions. EPS was $0.16 (adj. $1.05), supported by 19.3% EBITDA margin on $519M EBITDA. Segment performance varied, with Scent sales up ~5%. IFF reaffirmed full-year sales guidance of $10.6B–$10.9B and EBITDA of $2.0B–$2.15B.
Investment Thesis
Dividend Triangle
| 5-Yr Rev. Growth | 16.85 % |
| 5-Yr EPS Growth | 0.00 % |
| 5-Yr Div Growth | -12.05 % |
Potential Risks
| Debt/Equity | 0.65 |
| Financial Debt to EBITDA (TTM) | 2.85 |
| Current Ratio (Quarterly) | 1.85 |
| Credit Score | 46 |
Dividend Growth Perspective
| Dividend ($) | 1.6 |
| Dividend Yield Fwd | 2.30 % |
| Dividend Frequency | Quarterly |
| Average 5-Yr Yield | 2.85 % |
| Payout Ratio (%) | 168.30 |
| Cash Payout Ratio (%) | 123.20 |
| DGR 1-Yr (TTM) | 0.00 |
| DGR 3-Yr (TTM) | -20.65 |
| DGR 5-Yr (TTM) | -12.05 |
| DGR Streak | 21 |
| Chowder Score | -9.75 |
| Next DVD PMT | 01-09-26 |
Valuation
(Data for `ddm_growth_rate_years` field are missing to build DDM tables)
Video Tutorial: How to Read the Stock Cards DDM Valuation
| Market Cap | 18 B |
| PE Ratio | 0.00 |
| Fwd PE | 15.60 |
| Price to Book Ratio | 1.25 |
| DDM Valuation | 0 |
| Average 5-Yr PE | 228.59 |
| Value Score | 56 |